Literature DB >> 12595747

Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop.

K Nustad1, Y Lebedin, K O Lloyd, K Shigemasa, H W A de Bruijn, B Jansson, O Nilsson, K H Olsen, T J O'Brien.   

Abstract

CA 125 is found in body fluids in a variety of molecular weight forms. The largest species are found in normal abdominal fluid and cervical mucus. The present study therefore incorporated CA 125 derived from these sources as well as ascites fluid to investigate if the source of CA 125 influenced epitope characterization. Ascites-derived CA 125 varied in size from about 190 to about 2,700 kD. Cervical mucus-derived CA 125 treated with ultrasound changed its apparent size from more than 20,000 to 700 kD. Epitope mapping of antibodies was not grossly influenced by the size or source of CA 125 used as target. However, low-molecular-weight CA 125, i.e. ascites fractions CA 17/E, CA 17/F and CA 10/7, did show differences in certain assay combinations and cross-inhibition patterns which probably can be explained by steric effects due to the smaller size compared with the most abundant forms of CA 125 present in serum and other body fluids. The specificity of six new monoclonal antibodies to CA 125 was tested by cross-inhibition and immunometric assay combinations and compared to reference antibodies. One antibody, X306, belonged to the OC125-like antibodies. Four antibodies, X52, X75, X325 and VK8, were M11-like. The sixth antibody, 7C12, reacted with an epitope which was difficult to define. This antibody was inhibited by M11-like antibodies and OV197. However, used as an inhibitor, 7C12 inhibited only itself. We grouped it as an OV197-like antibody, but clearly different from OV197. The topography of epitopes was studied by analyzing all antibody pairs in immunoradiometric assays. These results confirmed the grouping of antibodies described above and are in accordance with previous findings that the highest signal is obtained using an OC125-like antibody or OV197 on the solid phase and an M11-like antibody as tracer. The composition of the sample in terms of high- and low-molecular-weight species of CA 125 was measured, with different responses depending on the antibody pair used. This might be one reason for discrepancies between assay results for CA 125 using different assays. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12595747     DOI: 10.1159/000068570

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  11 in total

1.  Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Authors:  Thapi Dharma Rao; Kay J Park; Peter Smith-Jones; Alexia Iasonos; Irina Linkov; Robert A Soslow; David R Spriggs
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-10

2.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

3.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

4.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

5.  Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways.

Authors:  M Kesimer; C Ehre; K A Burns; C W Davis; J K Sheehan; R J Pickles
Journal:  Mucosal Immunol       Date:  2012-08-29       Impact factor: 7.313

6.  Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16.

Authors:  Ilene K Gipson; Ulla Mandel; Balaraj Menon; Sandra Michaud; Ann Tisdale; Diana Campos; Henrik Clausen
Journal:  Glycobiology       Date:  2017-10-01       Impact factor: 4.313

7.  Phorbol 12-Myristate 13-Acetate Induces MUC16 Expression via PKCδ and p38 in Human Airway Epithelial Cells.

Authors:  Chang Hoon Bae; Hak Soo Kim; Si-Youn Song; Yong-Dae Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-08-27       Impact factor: 3.372

Review 8.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

9.  Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry.

Authors:  Florian Weiland; Katarina Fritz; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-09       Impact factor: 6.208

10.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.

Authors:  T Bjørge; A K Lie; E Hovig; R E Gislefoss; S Hansen; E Jellum; H Langseth; K Nustad; C G Tropé; A Dørum
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.